Page 305 - Vitamin D and Cancer

292 G.M. Zinser et al.

35. Chaudhry M, Sundaram S, Gennings C et al (2001) The vitamin D3 analog, ILX-23–7553,
enhances the response to adriamycin and irradiation in MCF-7 breast tumor cells. Cancer
Chemother Pharmacol 47:429–436
36. Posner GH, Crawford KR, Peleg S et al (2001) A non-calcemic sulfone version of the vitamin
D(3) analogue seocalcitol (EB 1089): chemical synthesis, biological evaluation and potency
enhancement of the anticancer drug adriamycin. Bioorg Med Chem 9:2365–2371
37. Sundaram S, Gewirtz DA (1999) The vitamin D3 analog EB 1089 enhances the response of
human breast tumor cells to radiation. Radiat Res 152:479–486
38. Petitjean A, Mathe E, Kato S et al (2007) Impact of mutant p53 functional properties on TP53
mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53
database. Hum Mut 28:622–629
39. Maruyama R, Aoki F, Toyota M et al (2006) Comparative genome analysis identifies the
vitamin D receptor gene as a direct target of p53-mediated transcriptional activation. Cancer
Res 66:4574–4583
40. Kommagani R, Caserta TM, Kadakia MP (2006) Identification of vitamin D receptor as a
target of p63. Oncogene 25:3745–3751
41. Roy D, Calaf G, Hei TK (2003) Role of vitamin D receptor gene in radiation-induced neo-
plastic transformation of human breast epithelial cell. Steroids 68:621–627
42. Saramaki A, Banwell CM, Campbell MJ et al (2006) Regulation of the human p21(waf1/cip1)
gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids
Res 34:543–554
43. Li QP, Qi X, Pramanik R et al (2007) Stress-induced c-jun-dependent vitamin D receptor
(VDR) activation dissects the non-classical VDR pathway from the classical VDR activity.
J Biol Chem 282:1544–1551
44. James SY, Mercer E, Brady M et al (1998) EB1089, a synthetic analogue of vitamin D,
induces apoptosis in breast cancer cells in vivo and in vitro. Br J Pharmacol 125:953–962
45. VanWeelden K, Flanagan L, Binderup L et al (1998) Apoptotic regression of MCF-7 xeno-
grafts in nude mice treated with the vitamin D3 analog, EB1089. Endocrinol 139:2102–2110
46. Flanagan L, Packman K, Juba B et al (2003) Efficacy of Vitamin D compounds to modulate
estrogen receptor negative breast cancer growth and invasion. J Steroid Biochem Mol Biol
84:181–192
47. Nolan E, Donepudi M, VanWeelden K et al (1998) Dissociation of vitamin D3 and anti-estro-
gen mediated growth regulation in MCF-7 breast cancer cells. Mol Cell Biochem 188:13–20
48. Valrance ME, Brunet AH, Welsh JE (2007) Vitamin D receptor-dependent inhibition of mam-
mary tumor growth by EB1089 and ultraviolet radiation in vivo. Endocrinol 148:4887–4894
49. Eisman JA, Macintyre I, Martin TJ et al (1980) Normal and malignant breast tissue is a target
organ for 1, 25-(OH)2 vitamin D3. Clin Endocrinol 13:267–272
50. Kemmis CM, Salvador SM, Smith KM et al (2006) Human mammary epithelial cells express
CYP27B1 and are growth inhibited by 25-hydroxyvitamin D-3, the major circulating form of
vitamin D3. J Nutr 136:887–892
51. Zinser G, Packman K, Welsh JE (2002) Vitamin D(3) receptor ablation alters mammary gland
morphogenesis. Development 129:3067–3076
52. Zinser GM, Welsh J (2004) Accelerated mammary gland development during pregnancy and
delayed postlactational involution in vitamin D3 receptor null mice. Mol Endocrinol
18:2208–2223
53. Brouwer DA, van Beek J, Ferwerda H et al (1998) Rat adipose tissue rapidly accumulates and
slowly releases an orally-administered high vitamin D dose. Br J Nutr 79:527–532
54. Townsend K, Banwell CM, Guy M et al (2005) Autocrine metabolism of vitamin D in normal
and malignant breast tissue. Clin Cancer Res 11:3579–3586
55. Rowling MJ, Kemmis CM, Taffany DA et al (2006) Megalin-mediated endocytosis of vitamin
D binding protein correlates with 25-hydroxycholecalciferol actions in human mammary
cells. J Nutr 136:2754–2759
56. Lipkin M, Newmark HL (1999) Vitamin D, calcium and prevention of breast cancer: a review.
J Am Coll Nutr 18:392S–397S